Trials / Completed
CompletedNCT04421027
A Study of Baricitinib (LY3009104) in Participants With COVID-19
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,525 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The reason for this study is to see if the study drug baricitinib is effective in hospitalized participants with COVID-19.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Baricitinib | Given orally |
| DRUG | Placebo | Given orally |
Timeline
- Start date
- 2020-06-12
- Primary completion
- 2021-02-12
- Completion
- 2021-06-10
- First posted
- 2020-06-09
- Last updated
- 2022-07-28
- Results posted
- 2022-03-24
Locations
96 sites across 13 countries: United States, Argentina, Brazil, Germany, India, Italy, Japan, Mexico, Puerto Rico, Russia, South Korea, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04421027. Inclusion in this directory is not an endorsement.